Presentation is loading. Please wait.

Presentation is loading. Please wait.

Plasma concentration-time profile after oral administration of a single dose. Plasma concentration-time profile after oral administration of a single dose.

Published byRaymonde Larrivée Modified over 5 years ago

Similar presentations

Presentation on theme: "Plasma concentration-time profile after oral administration of a single dose. Plasma concentration-time profile after oral administration of a single dose."— Presentation transcript:

1 Plasma concentration-time profile after oral administration of a single dose.
Plasma concentration-time profile after oral administration of a single dose. The components relevant to the pharmacokinetics of a drug’s concentration-time profile are the peak or maximum plasma concentration (Cmax) and the time when it occurs (Tmax), the area under the concentration-time curve (represented as shaded area), and the elimination t1/2 (determined using the blue lines). Tom N. Lea-Henry et al. CJASN 2018;13: ©2018 by American Society of Nephrology

Download ppt "Plasma concentration-time profile after oral administration of a single dose. Plasma concentration-time profile after oral administration of a single dose."

Similar presentations

A service provided to medicine by Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License Pharmacokinetics.

A service provided to medicine by Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License Pharmacokinetics.
415 PHT Plasma Level – Time Curve

415 PHT Plasma Level – Time Curve
Source: Frank M. Balis Concentration and Effect vs. Time Conc./ Amount Effect [% of E MAX ] Time Central Compartment Peripheral Compartment Effect Compartment.

Source: Frank M. Balis Concentration and Effect vs. Time Conc./ Amount Effect [% of E MAX ] Time Central Compartment Peripheral Compartment Effect Compartment.
Drug Response Relationships

Drug Response Relationships
Volume 9, Issue 8, Pages (August 2017)

Volume 9, Issue 8, Pages (August 2017)
Applications of Pharmacokinetics

Applications of Pharmacokinetics
Pharmacokinetics. Pharmacokinetics Oral administration Blood concentration after oral administration Cmax Concentration Concentration tmax Time Time.

Pharmacokinetics. Pharmacokinetics Oral administration Blood concentration after oral administration Cmax Concentration Concentration tmax Time Time.
Suggested approach to patients with dabigatran-associated bleeding

Suggested approach to patients with dabigatran-associated bleeding
Positive interactions between the basic and translational research, clinical research, patient care, and training components of an academic dialysis access.

Positive interactions between the basic and translational research, clinical research, patient care, and training components of an academic dialysis access.
Comparison of the model incorporating daily dose to that incorporating Cmax. Comparison of the model incorporating daily dose to that incorporating Cmax.

Comparison of the model incorporating daily dose to that incorporating Cmax. Comparison of the model incorporating daily dose to that incorporating Cmax.
Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function  Susan E. Shoaf, Patricia Bricmont, Suresh.

Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function  Susan E. Shoaf, Patricia Bricmont, Suresh.
Plasma concentration–time profile, relative bioavailability and pharmacokinetic (PK) parameters of 4 mg TAK-228 in the single-agent QD PK run-in period,

Plasma concentration–time profile, relative bioavailability and pharmacokinetic (PK) parameters of 4 mg TAK-228 in the single-agent QD PK run-in period,
Voriconazole tissue and fluid concentrations in humans as multiples of the maximal or simultaneously measured concentration in plasma (μg/ml) after systemic.

Voriconazole tissue and fluid concentrations in humans as multiples of the maximal or simultaneously measured concentration in plasma (μg/ml) after systemic.
Pharmacokinetics of icodextrin in peritoneal dialysis patients

Pharmacokinetics of icodextrin in peritoneal dialysis patients
Figure Diagrammatic levodopa pharmacokinetics after single doses of immediate release (IR) carbidopa/levodopa (CD/LD) and 3 strengths of extended release.

Figure Diagrammatic levodopa pharmacokinetics after single doses of immediate release (IR) carbidopa/levodopa (CD/LD) and 3 strengths of extended release.
Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.

Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.
PTA for AUC/MIC ratio ≥800 for each 48-hour AUC: AUC0 to 48 (A), AUC48 to 96 (B), and AUC96 to 144 (C). PTA for AUC/MIC ratio ≥800 for each 48-hour AUC:

PTA for AUC/MIC ratio ≥800 for each 48-hour AUC: AUC0 to 48 (A), AUC48 to 96 (B), and AUC96 to 144 (C). PTA for AUC/MIC ratio ≥800 for each 48-hour AUC:
Thirty-day survival curves for the rapid versus slow correction rate groups are not significantly different. Thirty-day survival curves for the rapid versus.

Thirty-day survival curves for the rapid versus slow correction rate groups are not significantly different. Thirty-day survival curves for the rapid versus.
Scatterplots showing the association between the three peritoneal equilibration test (PET) parameters. Scatterplots showing the association between the.

Scatterplots showing the association between the three peritoneal equilibration test (PET) parameters. Scatterplots showing the association between the.
Within-group comparisons of adjusted mean±SEM of absolute change in peak systolic strain (%) from baseline to 12 months using the American Heart Association.

Within-group comparisons of adjusted mean±SEM of absolute change in peak systolic strain (%) from baseline to 12 months using the American Heart Association.

Similar presentations

Ads by Google